Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Selzentry Wins FDA Approval For HIV

This article was originally published in The Pink Sheet Daily

Executive Summary

First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.

You may also be interested in...



Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events

Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.

Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events

Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.

Reanalyzed MERIT Data Suggests Selzentry Efficacy Matches HIV Standard Of Care

Enhanced Trofile assay reveals previous data included patients with HIV variants who should have been excluded, Pfizer and Monogram Biosciences report at ICAAC.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel